Impact of Viral Infections on Blood Cell Development
Official title: Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors
Run by Assistance Publique - Hôpitaux de Paris · NCT06458504 · Data updated 2026-11-12
This study is trying to see how HIV and COVID-19 affect the development of blood cells in both healthy people and those with HIV by looking at their bone marrow.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Boulogne-Billancourt) |
| Status | Recruiting |
| Started | October 25, 2024 |
| Main results expected | March 2026 |
| Study ends | March 2026 |
| Registry record updated | March 20, 2025 |
| Trial ID | NCT06458504 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include HIV-positive patients and healthy individuals undergoing bone marrow evaluations at Ambroise Paré Hospital.
✕Probably not a fit
Patients without any hematological concerns or those not managed at Ambroise Paré Hospital may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate how HIV-1 and SARS-CoV-2 affect hematopoietic stem and progenitor cells (HSPC) and their role in blood cell development. It will evaluate the susceptibility of HSPC to these viruses and assess the potential modulation of the bone marrow environment by infected cells. The study will involve both HIV-positive patients and healthy subjects undergoing bone marrow biopsies or myelograms at Ambroise Paré Hospital. The findings could provide insights into the mechanisms of virus-induced immunosuppression and its effects on hematopoiesis.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of immunosuppression in patients with HIV and COVID-19.
How similar studies have gone: While studies have explored the effects of HIV on hematopoiesis, the specific investigation of SARS-CoV-2's impact on HSPC is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: HIV patients : * HIV-positive patients with a negative or positive viral load. * managed at Ambroise Paré Hospital. * patients with a bone marrow biopsy or myelogram performed as part of their care. Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology. Management at Ambroise Paré Hospital. Exclusion Criteria: \-
Where it's running
-
Hematology and interne medicine department, Ambroise Paré hospital - APHP
Boulogne-Billancourt, France Recruiting
Study contacts
- Principal investigator: Claude CAPRON, MD, PhD — Laboratory of Immunology, Ambroise Paré hospital - APHP
- Study coordinator: Claude CAPRON, MD, PhD
- Email: claude.capron@aphp.fr
- Phone: + 33 01 49 09 58 47
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Vaccine formulations containing mRNA-1273 and mRNA-1283 to see if they boost immunity and remain safe
This study tests whether two mRNA vaccines that target SARS-CoV-2 can safely generate an immune response in older adults and people with risk factors.
-
Vaccine study to test mRNA-1283 in children and infants
A vaccine study will test two dose levels of mRNA-1283 in kids from 6 months to under 12 years to see which dose works best, using mRNA-1273 as a comparison.
-
Secutrelvir for high-risk COVID-19 patients who are not in hospital
This study tests whether secutrelvir can help nonhospitalized teens and adults with COVID-19 who are at high risk of getting worse.
-
Blocking BCL-2 when starting HIV treatment to help infected cells die (INITIATE)
This trial will try giving the BCL-2 blocker venetoclax to people with newly diagnosed HIV who are starting ART to see if it helps infected cells die and reduces the hidden HIV reservoir.
-
Kisspeptin to measure GnRH neuron function in people with and without post-COVID-19 syndrome
We will give one intravenous kisspeptin dose and take frequent blood samples to see if people with post-COVID-19 syndrome have different GnRH/LH hormone responses than people who had COVID but did not develop long COVID.
-
Switching to once-daily dolutegravir plus lamivudine for transgender women with HIV
This will test whether switching to once-daily dolutegravir plus lamivudine keeps HIV suppressed and is safe for transgender women already on suppressive antiretroviral therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.